Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Case Report
Neoadjuvant Chemotherapy in the Management of Extraovarian Yolk Sac Tumor: A Case Report and A Review of the Literature
Susana Mustafa, Amnon Amit, Ari Reiss and Zeev Weiner*Department of Obstetrics and Gynecology, Rambam Health Care Campus, Ruth and Bruce Rappaport, Faculty of Medicine Technion-Israel Institute of Technology,Haifa, Israel
- *Corresponding Author:
- Zeev Weiner
MD, Department of Obstetrics and Gynecology
Rambam Health Care Campus, Ruth and Bruce Rappaport
Faculty of Medicine Technion-Israel Institute of Technology, Haifa, Israel
Tel: 9728542536
Fax: 9728542453
E-mail: z_weiner@rambam.health.gov.il
Received date: September 17, 2014; Accepted date: October 16, 2014; Published date: October 18, 2014
Citation: Mustafa S, Amit A, Reiss A, Weiner Z (2014) Neoadjuvant Chemotherapy in the Management of Extraovarian Yolk Sac Tumor: A Case Report and A Review of the Literature. J Clin Exp Pathol 4:198. doi:10.4172/2161-0681.1000198
Copyright: ©Mustafa S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Extraovarian yolk sac tumor (YST) is an extremely rare malignancy occurring mainly in girls and young women of childbearing ages and commonly treated with fertility-sparing surgery and postoperative adjuvant chemotherapy. We report a case treated with neoadjuvant chemotherapy (NACT) followed by cytoredutive surgery and adjuvant chemotherapy.
A 32-year-old single woman came for a second opinion following explorative laparotomy secondary to pelvic mass and histologic results of an undetermined malignancy. Our evaluation revealed a yolk sac tumor involving the cecum with a cutaneous fistula and pelvic infection. The patient was treated with three courses of Bleomycin, Etoposide and Cisplatin (BEP) followed by an optimal cytoreductive surgery and another two courses of Etoposide and Platinum-AQ (EP). There is no evidence of disease during a two years follow-up.
Conclusion: NACT followed by fertility sparing surgery should be considered as an alternative to primary debulking surgery in advanced YSTs.
